Uploaded July 2021 | Updated November 2026, 1 day ago
UCLA project scientist Mark DeWitt discusses a combined IGI, UCLA, and UCSF effort in developing a CRISPR-based clinical product to correct sickle cell disease. Listen to Mark as he describes how his team went from a bench genome-editing protocol to an accepted Investigational New Drug (IND).
IGI Seminar Series - May 4, 2021
UCLA project scientist Mark DeWitt discusses a combined IGI, UCLA, and UCSF effort in developing a CRISPR-based clinical product to correct sickle cell disease. Listen to Mark as he describes how his team went from a bench genome-editing protocol to an accepted Investigational New Drug (IND).
IGI Seminar Series - May 4, 2021










